0.2066

3.82% -0.0082

Pre-market: .20 -0.0066 -3.19%

Vistagen Therapeutics Inc (VTGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vistagen Therapeutics Inc stock is traded at $0.2066, with a volume of 989.74K. It is down -3.82% in the last 24 hours and down -12.49% over the past month. Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Previous Close:

$0.2148

Open:

$0.206

24h Volume:

989.74K

Relative Volume:

0.85

Market Cap:

$9.17M

Revenue:

$1.04M

Net Income/Loss:

$-67.50M

P/E Ratio:

-0.1075

EPS:

-1.9222

Net Cash Flow:

$-60.67M

1W Performance:

-16.08%

1M Performance:

-12.49%

6M Performance:

-66.21%

1Y Performance:

-94.83%

1-Day Range:

$0.00

1-Week Range:

$0.20

$0.2445

52-Week Range:

$0.198

$5.14

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name

Vistagen Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

650-577-3600

Address

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

@vistagen

Next Earnings Date

2026-11-12

Latest SEC Filings

VTGN's Discussions on Twitter

Compare VTGN vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTGN Vistagen Therapeutics Inc	0.2066	9.17M	1.04M	-67.50M	-60.67M	-1.9222
VRTX Vertex Pharmaceuticals Inc	498.50	126.35B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	226.30	90.35B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	778.36	80.14B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	818.30	51.46B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	193.52	41.48B	742.00K	-1.37B	-1.07B	-7.0731

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-17-25	Downgrade	Jefferies	Buy → Hold
Dec-17-25	Downgrade	Maxim Group	Buy → Hold
Dec-17-25	Downgrade	Stifel	Buy → Hold
Dec-17-25	Downgrade	William Blair	Outperform → Mkt Perform
Dec-07-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Upgrade	Maxim Group	Hold → Buy
Jul-22-22	Downgrade	Jefferies	Buy → Hold
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
May-20-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Initiated	Jefferies	Buy
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy
Feb-08-18	Reiterated	Chardan Capital Markets	Buy
Mar-28-17	Initiated	Maxim Group	Buy

View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

Sep 25, 2026

Top US Stock Movers: Gainers and Losers in Today's Session - ChartMill

Sep 25, 2026

Form 8K VistaGen Therapeutics Inc For: 25 September By Investing.com - Investing.com Nigeria

Sep 25, 2026

Three anxiety drug trials missed their goals. Vistagen (VTGN) proposes another after one met its goal. - Stock Titan

Sep 25, 2026

Sep 24, 2026

Vistagen Therapeutics Shares Positive Fasedienol Nasal Spray Data at Psych Congress 2026 - Kalkine Media

Sep 24, 2026

Sep 23, 2026

Top US Stock Movers for 2026-09-23: VSA Up 135.0%, JAGX Down 73.74% - ChartMill

Sep 23, 2026

Small Cap Stocks To Keep An Eye OnSeptember 23rd - MarketBeat

Sep 23, 2026

Let's take a look at the stocks that are in motion in today's session. - ChartMill

Sep 23, 2026

Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Benzinga

Sep 23, 2026

Sep 22, 2026

Year‑long nasal spray use at Vistagen (NASDAQ: VTGN) lowers social anxiety scores as FDA talks approach - Stock Titan

Sep 22, 2026

Sep 11, 2026

Vistagen Therapeutics shareholders elect board members and approve key proposals By Investing.com - Investing.com Australia

Sep 11, 2026

Form 8K VistaGen Therapeutics Inc For: 11 September By Investing.com - Investing.com Nigeria

Sep 11, 2026

Form 8K VistaGen Therapeutics Inc For: 11 September By Investing.com - Investing.com Canada

Sep 11, 2026

Form 8K VistaGen Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa

Sep 11, 2026

VistaGen Stockholders Reaffirm Board, Governance and Oversight - TipRanks

Sep 11, 2026

Vistagen Therapeutics shareholders elect board members and approve key proposals - Investing.com Canada

Sep 11, 2026

Stockholders at Vistagen (NASDAQ: VTGN) back board slate, executive pay and KPMG - Stock Titan

Sep 11, 2026

Vistagen Therapeutics shareholders elect board members and approve key proposals - Investing.com Nigeria

Sep 11, 2026

Sep 10, 2026

Vistagen to Present at Psych Congress 2026 - GlobeNewswire

Sep 10, 2026

Sep 03, 2026